M. Curado, B. Edwards, and H. Shin, Cancer incidence in five continents, Volume IX, 2007.

W. Travis, E. Brambilla, and M. Noguchi, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.6, issue.2, pp.244-285, 2011.
DOI : 10.1097/JTO.0b013e318206a221
URL : https://hal.archives-ouvertes.fr/inserm-00561753

D. Garfield, J. Cadranel, and M. Wislez, The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases, Journal of Thoracic Oncology, vol.1, issue.4, pp.344-359, 2006.
DOI : 10.1016/S1556-0864(15)31593-8

K. Tsuta, M. Kawago, and E. Inoue, The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations, Lung Cancer, vol.81, issue.3, pp.371-376, 2013.
DOI : 10.1016/j.lungcan.2013.06.012

A. Warth, T. Muley, and M. Meister, The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival, Journal of Clinical Oncology, vol.30, issue.13, pp.1438-1446, 2012.
DOI : 10.1200/JCO.2011.37.2185

A. Yoshizawa, N. Motoi, and G. Riely, Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases, Modern Pathology, vol.57, issue.5, pp.653-664, 2011.
DOI : 10.1002/1097-0142(19860415)57:8<1555::AID-CNCR2820570820>3.0.CO;2-N

D. Garfield, J. Cadranel, and H. West, Bronchioloalveolar Carcinoma: The Case for Two Diseases, Clinical Lung Cancer, vol.9, issue.1, pp.24-29, 2008.
DOI : 10.3816/CLC.2008.n.004

O. Breathnach, D. Kwiatkowski, and D. Finkelstein, Bronchioloalveolar carcinoma of the lung: Recurrences and survival in patients with stage I disease, The Journal of Thoracic and Cardiovascular Surgery, vol.121, issue.1, pp.42-47, 2001.
DOI : 10.1067/mtc.2001.110190

J. Ebbert, L. Chhatwani, and M. Aubry, Clinical Features of Bronchioloalveolar Carcinoma with New Histologic and Staging Definitions, Journal of Thoracic Oncology, vol.5, issue.8, pp.1213-1220, 2010.
DOI : 10.1097/JTO.0b013e3181e2f645

C. Casali, G. Rossi, and A. Marchioni, A Single Institution-Based Retrospective Study of Surgically Treated Bronchioloalveolar Adenocarcinoma of the Lung: Clinicopathologic Analysis, Molecular Features, and Possible Pitfalls in Routine Practice, Journal of Thoracic Oncology, vol.5, issue.6, pp.830-836, 2010.
DOI : 10.1097/JTO.0b013e3181d60ff5

A. Carretta, P. Ciriaco, and G. Melloni, Surgical Treatment of Multiple Primary Adenocarcinomas of the Lung, The Thoracic and Cardiovascular Surgeon, vol.57, issue.01, pp.30-34, 2009.
DOI : 10.1055/s-2008-1038989

R. Daly, V. Trastek, and P. Pairolero, Bronchoalveolar carcinoma: Factors affecting survival, The Annals of Thoracic Surgery, vol.51, issue.3, pp.368-376, 1991.
DOI : 10.1016/0003-4975(91)90847-J

P. Volpino, A. Cavallaro, and R. Cangemi, Comparative analysis of clinical features and prognostic factors in resected bronchioloalveolar carcinoma and adenocarcinoma of the lung, Anticancer Res, vol.23, pp.4959-4965, 2003.

M. Duruisseaux, M. Antoine, and N. Rabbe, The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation, Lung Cancer, vol.83, issue.3, pp.334-340, 2014.
DOI : 10.1016/j.lungcan.2013.12.016

A. Hata, N. Katakami, and S. Fujita, Frequency of EGFR and KRAS Mutations in Japanese Patients with Lung Adenocarcinoma with Features of the Mucinous Subtype of Bronchioloalveolar Carcinoma, Journal of Thoracic Oncology, vol.5, issue.8, pp.1197-1200, 2010.
DOI : 10.1097/JTO.0b013e3181e2a2bc

M. , A. M. Baudrin, and L. , Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib, Lung Cancer, vol.68, pp.185-191, 2010.

K. Finberg, L. Sequist, and V. Joshi, Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features, The Journal of Molecular Diagnostics, vol.9, issue.3, pp.320-326, 2007.
DOI : 10.2353/jmoldx.2007.060182

Y. Sakuma, S. Matsukuma, and M. Yoshihara, Gene-Mutation Analyses for Japanese Lung Adenocarcinomas, American Journal of Clinical Pathology, vol.128, issue.1, pp.100-108, 2007.
DOI : 10.1309/WVXFGAFLAUX48DU6

P. Goldstraw, J. Crowley, and K. Chansky, The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, Journal of Thoracic Oncology, vol.2, issue.8, pp.706-714, 2007.
DOI : 10.1097/JTO.0b013e31812f3c1a

M. , R. N. Marchal, and J. , Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death, Cancer Res, vol.63, pp.1405-1412, 2003.

T. Lynch, D. Bell, and R. Sordella, Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.350, issue.21, pp.2129-2139, 2004.
DOI : 10.1056/NEJMoa040938

E. Yi, J. Chung, and K. Kulig, Detection of Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Non-Small Cell Lung Cancer and Related Issues in ALK Inhibitor Therapy, Molecular Diagnosis & Therapy, vol.108, issue.18, pp.143-150, 2012.
DOI : 10.1002/cncr.27409

E. Lazzeri and P. Romagnani, CXCR3-binding Chemokines: Novel Multifunctional Therapeutic Targets, Current Drug Targets - Immune, Endocrine & Metabolic Disorders, vol.5, issue.1, pp.109-118, 2005.
DOI : 10.2174/1568008053174723

R. Strieter, C. Addison, and J. Ehlert, Use of Immunodeficient Mice for the Evaluation of CXC Chemokines in the Regulation of Tumor-associated Angiogenesis, ILAR Journal, vol.40, issue.4, pp.175-182, 1999.
DOI : 10.1093/ilar.40.4.175

P. Romagnani, F. Annunziato, and L. Lasagni, Cell cycle???dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity, Journal of Clinical Investigation, vol.107, issue.1, pp.53-63, 2001.
DOI : 10.1172/JCI9775

S. Moriai, M. Takahara, and T. Ogino, Production of Interferon-??-Inducible Protein-10 and Its Role as an Autocrine Invasion Factor in Nasal Natural Killer/T-Cell Lymphoma Cells, Clinical Cancer Research, vol.15, issue.22, pp.6771-6779, 2009.
DOI : 10.1158/1078-0432.CCR-09-1052

A. 28-zipin-roitman, T. Meshel, and O. Sagi-assif, CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma Cells, Cancer Research, vol.67, issue.7, pp.3396-3405, 2007.
DOI : 10.1158/0008-5472.CAN-06-3087

T. Murakami, K. Kawada, and M. Iwamoto, The role of CXCR3 and CXCR4 in colorectal cancer metastasis, International Journal of Cancer, vol.27, issue.2, pp.276-287, 2013.
DOI : 10.1016/j.tips.2005.11.001

A. Mulligan, I. Raitman, and L. Feeley, Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry, Clinical Cancer Research, vol.19, issue.2, pp.336-346, 2013.
DOI : 10.1158/1078-0432.CCR-11-3314

X. Ma, K. Norsworthy, and N. Kundu, CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model, Molecular Cancer Therapeutics, vol.8, issue.3, pp.490-498, 2009.
DOI : 10.1158/1535-7163.MCT-08-0485

T. Walser, S. Rifat, and X. Ma, Antagonism of CXCR3 Inhibits Lung Metastasis in a Murine Model of Metastatic Breast Cancer, Cancer Research, vol.66, issue.15, pp.7701-7707, 2006.
DOI : 10.1158/0008-5472.CAN-06-0709

N. Giuliani, S. Bonomini, and P. Romagnani, CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival, Haematologica, vol.91, pp.1489-1497, 2006.

C. Billottet, C. Quemener, and A. Bikfalvi, CXCR3, a double-edged sword in tumor progression and angiogenesis, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1836, issue.2, pp.287-295, 2013.
DOI : 10.1016/j.bbcan.2013.08.002

A. Fulton, The chemokine receptors CXCR4 and CXCR3 in cancer, Current Oncology Reports, vol.179, issue.2, pp.125-131, 2009.
DOI : 10.4049/jimmunol.179.6.4272

H. Mousa, A. Lleo, and P. Invernizzi, Advances in pharmacotherapy for primary biliary cirrhosis, Expert Opinion on Pharmacotherapy, vol.145, issue.3, pp.633-643, 2015.
DOI : 10.1053/j.gastro.2013.06.052
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591873

K. Raemdonck, P. Van-den-steen, and S. Liekens, CXCR3 ligands in disease and therapy, Cytokine & Growth Factor Reviews, vol.26, issue.3, pp.311-327, 2015.
DOI : 10.1016/j.cytogfr.2014.11.009

D. Datta, J. Flaxenburg, and S. Laxmanan, Ras-induced Modulation of CXCL10 and Its Receptor Splice Variant CXCR3-B in MDA-MB-435 and MCF-7 Cells: Relevance for the Development of Human Breast Cancer, Cancer Research, vol.66, issue.19, pp.9509-9518, 2006.
DOI : 10.1158/0008-5472.CAN-05-4345

R. Phelps, B. Johnson, and D. Ihde, NCI-navy medical oncology branch cell line data base, Journal of Cellular Biochemistry, vol.10, issue.S24, pp.32-91, 1996.
DOI : 10.7326/0003-4819-113-10-764